Delcath Systems, Inc. DCTH today
announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs
Advisory Committee (ODAC) voted 16 to 0 with no abstentions that benefits of
treatment with Delcath's Melblez^TM Kit (Melblez (melphalan) for Injection for
use with the Delcath Hepatic Delivery System) for the treatment of patients
with unresectable ocular melanoma metastatic to the liver do not outweigh the
risks associated with the procedure.
The FDA is not bound by the recommendation of its advisory committee, but will
consider the committee's guidance as it evaluates the Melblez Kit New Drug
Application (NDA). The Prescription Drug User Fee Act (PDUFA) goal date for
completion of the FDA's review and decision regarding approval of the Melblez
Kit NDA is September 13, 2013.
"As we conveyed during the presentation to the ODAC, we believe our clinical
trial data support Melblez Kit as an effective treatment option offering
clinical benefits to patients with unresectable metastatic ocular melanoma in
the liver" said Eamonn P. Hobbs, President and CEO of Delcath Systems. "While
we were disappointed in today's outcome, we will continue to work closely with
the FDA throughout its ongoing evaluation of Melblez Kit. We remain committed
to providing access to this promising new treatment for patients who have few
choices with regard to treatments."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in